Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (4)

2024

  1. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

2023

  1. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

2021

  1. Ultra-low dose whole-body CT for attenuation correction in a dual tracer PET/CT protocol for multiple myeloma

    Physica Medica, Vol. 84, pp. 1-9

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187